Healthcare Providers and Services
Company Overview of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...
1275 York Avenue
New York, NY 10065
Founded in 1884
Key Executives for Memorial Sloan Kettering Cancer Center
Chief Executive Officer and President
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Compensation as of Fiscal Year 2016.
Memorial Sloan Kettering Cancer Center Key Developments
The Multiple Myeloma Research Foundation, Inc Announces the Collaboration with Memorial Sloan Kettering Cancer Center to Launch a New Clinical Trial for Multiple Myeloma (MM) Patients
Sep 13 16
The Multiple Myeloma Research Foundation Inc. announced a collaboration with Memorial Sloan Kettering Cancer Center to launch a new clinical trial for multiple myeloma (MM) patients. The trial, Carfilzomib, Lenalidomide, Dexamethasone in Newly-Diagnosed Multiple Myeloma: a Translational MRD Study, will integrate highly effective, modern combination therapy with genetic sequencing, to help define predictors of sustained MRD negativity. MRD is defined as the level of disease still detectable in MM patients after their treatment regimen is completed. Recent work has shown that very low or undetectable levels of MRD after completion of treatment (i.e., a “deep response”) is associated with improved patient outcomes including longer survival. MRD measurement may offer a faster and more accurate assessment of how effective a treatment is in an individual patient; use of this test, pending approval by the US Food and Drug Administration, could allow clinical trials to proceed more rapidly, thereby cutting costs and potentially speeding new treatments to patients more quickly than ever before. The sensitivity of MRD measurement also holds the promise to help doctors determine –in the coming future- if and when treatment may be stopped or re-started based on a patient’s MRD status.
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies
Sep 7 16
Fate Therapeutics, Inc. announced a partnership with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines. Research and development activities under the multi-year collaboration will be led by Michel Sadelain, M.D., Ph.D., Director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at Memorial Sloan Kettering Cancer Center. The collaboration unites research, preclinical development and manufacturing work currently being conducted independently at Fate Therapeutics and Memorial Sloan Kettering to accelerate the clinical translation of T-cell product candidates derived from engineered pluripotent cells. Collectively, the groups have amassed significant and complementary expertise necessary to deliver off-the-shelf T-cell immunotherapies, including the engineering, maintenance and expansion of induced pluripotent cell lines and the scalable generation of T cells with enhanced safety profiles and effector functions. In connection with the partnership, Fate Therapeutics has exclusively licensed from Memorial Sloan Kettering foundational intellectual property covering induced pluripotent cell-derived immune cells, including T cells and NK cells derived from pluripotent cells engineered with chimeric antigen receptors, for human therapeutic use. Additionally, Fate Therapeutics maintains an option to exclusively license intellectual property arising from all research and development activities under the collaboration.
Juno Therapeutics Signs License Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics
Aug 8 16
Juno Therapeutics has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics. The contract has been signed for a novel fully-human binding domain targeting B-cell maturation antigen along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialisation of chimeric antigen receptor cell therapies for patients with multiple myeloma. The binding domains were established under a collaboration contract between both firms. The parties expect the BCMA CAR to enter human testing as early as the first half of 2017. MSK and Eureka Therapeutics are eligible to receive an undisclosed upfront payment, additional payments upon the achievement of undisclosed clinical, regulatory, and commercial milestones, and royalties on net sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|